Rowan-Virtua SOM and Durin recently announced the publication of their results of a blood test for Alzheimer’s disease. This test is the first of its kind and has been developed to detect the presence of the disease in its early stages.
Alzheimer’s disease is a progressive neurological disorder that affects millions of people around the world. It is characterized by memory loss, confusion, and difficulty in performing daily activities. Currently, diagnosis of the disease is made through a combination of physical and cognitive tests, as well as brain scans.
The new blood test developed by Rowan-Virtua SOM and Durin is based on a biomarker called amyloid-beta. This biomarker is found in the blood of people with Alzheimer’s disease and can be used to detect the presence of the disease in its early stages. The test works by measuring the levels of amyloid-beta in the blood and comparing them to a reference range. If the levels are higher than the reference range, it indicates that the person may have Alzheimer’s disease.
The research team conducted a study involving over 500 participants, both with and without Alzheimer’s disease. The results showed that the blood test was able to accurately detect the presence of Alzheimer’s disease in over 90% of cases. The test was also able to distinguish between those with mild cognitive impairment and those without.
The results of this study are promising and could lead to earlier diagnosis and treatment of Alzheimer’s disease. Early diagnosis and treatment can help slow down the progression of the disease and improve quality of life for those affected.
Rowan-Virtua SOM and Durin are continuing to work on improving the accuracy of the test and making it available to more people. They hope that their work will help lead to better outcomes for those affected by Alzheimer’s disease.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
- Source: Plato Data Intelligence: PlatoAiStream